Systemic sclerosis & Raynaud's
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series
Authors' conclusion
Teclistamab induced deep tissue depletion of B-cells and plasma cells and rapid clinical and serological responses, with evidence for resolution of inflammation and potential modification of fibrotic processes.
Study context
- Population
- Patients with severe and treatment-refractory systemic sclerosis (SSc)completed 1 cycle
- Participants
- 10 patients
- Outcome
- Revised ACR-CRISS 25 and 50 responses
- Follow-up
- Median 3.75 months (IQR: 2.5 months)
Methodological detailsoff-label therapy
- Off-label therapy
Main finding
As reported in the abstract
median follow-up 3.75 months (IQR: 2.5 months)
Revised American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) 25 response
71%
Revised ACR-CRISS 50 response
43%
Observational data: associations, not effects.
Further findings
Antitopoisomerase antibody titres, median reduction
- Median reduction in antitopoisomerase antibody titres (IQR: 39%)
- 70.6%
- Accompanied by decreases in serum IgG and vaccination titres
FVC in patients with ILD, median increase · week 12
- Median increase in FVC (IQR: 15%)
- 7%
- Radiographic and functional improvement observed by week 12
Modified Rodnan skin score, median decrease
- Median decrease in modified Rodnan skin score (IQR: 17.9%)
- 35.9%
- Accompanied by reductions in fibroblast activation protein (FAP)-alpha-positive fibroblasts in skin biopsy specimens
Original publication
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series. Ann Rheum Dis. Published 19 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →